The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients with chronic kidney disease (CKD) after acute myocardial infarction (AMI) are unclear.
We analyzed data from the Taiwan National Health Insurance Research Database between March 1st, 2009 and December 31st, 2011. A total of 1025 AMI patients with diabetes with chronic kidney disease were selected as the study cohort. The study evaluated the cardiovascular safety and efficacy of sitagliptin by comparing 205 subjects (20%) who use sitagliptin to 820 matched subjects (80%) who do not. The primary outcomes included myocardial infarction, ischemic stroke or cardiovascular death.
Primary composite outcomes occurred in 54 patients in the sitagliptin group (26.3%) and in 164 patients in the comparison group (20.0%) (HR, 1.32; 95% CI, 0.97–1.79; P = 0.079) during the mean follow-up of 1.02 years (SD = 0.71 years). The sitagliptin group had similar risks of ischemic stroke, all-cause mortality or hospitalization for heart failure (HF) compared to the non-sitagliptin group (P = 0.938, 0.523 and 0.795 respectively). However, sitagliptin use was associated with increased risks of recurrent myocardial infarction (HR, 1.73; 95% CI, 1.15–2.58; P = 0.008) and percutaneous coronary revascularization (HR, 1.43; 95% CI, 1.04–1.95; P = 0.026).
Among type 2 diabetic patients with CKD after AMI, the use of sitagliptin was not associated with an increased risk of cardiovascular death, ischemic stroke or hospitalization for HF but was associated with increased risks of recurrent MI and percutaneous coronary revascularization.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to International Journal of Cardiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Epidemiology of cardiovascular complications in type 2 diabetes mellitus.Acta Diabetol. 2003; 40: S358-S361
- Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005.Circulation. 2009; 119: 1728-1735
- Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.J. Am. Soc. Nephrol. 2008; 19: 182-187
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet. 1998; 352: 837-853
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N. Engl. J. Med. 2008; 358: 2560-2572
- Long-term effects of intensive glucose lowering on cardiovascular outcomes.N. Engl. J. Med. 2011; 364: 818-828
- KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease.Am. J. Kidney Dis. 2007; 49: S12-S154
- Oral antihyperglycemic therapy for type 2 diabetes: scientific review.JAMA. 2002; 287: 360-372
- Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease.Am. J. Kidney Dis. 2000; 35: 500-505
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N. Engl. J. Med. 2007; 356: 2457-2471
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.Lancet. 2006; 368: 1696-1705
- Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.Am. J. Cardiol. 2012; 110: 826-833
- All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.Diabetes Obes. Metab. 2014; 16: 231-236
- Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.BMJ. 2013; 346: f2267
- Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.J. Am. Heart Assoc. 2013; 2: e003277
- Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients.Basic Res. Cardiol. 2012; 107: 233
- Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.Diabetes Care. 2013; 36: 1067-1073
- Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.Am. J. Kidney Dis. 2013; 61: 579-587
- Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan.Pharmacoepidemiol. Drug Saf. 2011; 20: 236-242
- Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease.Atherosclerosis. 2014; 232: 224-230
- Identification of individuals with CKD from Medicare claims data: a validation study.Am. J. Kidney Dis. 2005; 46: 225-232
- Validation of acute myocardial infarction cases in the National Health Insurance Research Database in Taiwan.J. Epidemiol. 2014; 24: 500-507
- Standardized Definitions for End Point Events in Cardiovascular Trials.2010: 37
- Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection.JAMA. 2012; 308: 1906-1914
- Alogliptin after acute coronary syndrome in patients with type 2 diabetes.N. Engl. J. Med. 2013; 369: 1327-1335
- Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.N. Engl. J. Med. 2013; 369: 1317-1326
- Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.Am. Heart J. 2013; 166 (e7): 983-989
- Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.Circ. J. 2013; 77: 1337-1344
- Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.Metab. Clin. Exp. 2014; 63: 1141-1148
Published online: December 03, 2014
Accepted: December 2, 2014
Received in revised form: November 30, 2014
Received: November 6, 2014
© 2014 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.